All stock lists
Spero Therapeutics, Inc. (NASDAQ:SPRO)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.07-0.04 (-3.60%)
Market cap
$62.3M
Health Score
Analyst consensus
Listed since
Nov 2, 2017
Website
Insider Score
––Not scored
SPRO Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
SPRO analyst forecast
SPRO analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
SPRO 12-month price target
No published price targets in the last 12 months.
Best analysts covering SPRO
- HC Wainwright & Co.50%success rate · 18 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SPRO analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-30 |
| — | Evercore ISI Group | In Line | — | — | Downgraded | 2024-12-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-02 |
| — | TD Cowen | Hold | — | — | Downgraded | 2024-11-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-03 |
| — | TD Cowen | Buy | — | — | Upgraded | 2024-08-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-09-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-07-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-04-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-09-26 |
| — | Evercore ISI Group | Outperform | — | — | Upgraded | 2022-09-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-08-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-05-23 |
| — | Berenberg | Hold | — | — | Downgraded | 2022-05-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2022-05-17 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2022-05-04 |
| — | Evercore ISI Group | In Line | — | — | Downgraded | 2022-05-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-04-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-03-21 |
| — | Oppenheimer | Perform | — | — | Downgraded | 2021-10-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-01-22 |
| — | Berenberg | Buy | — | — | Reiterated | 2020-12-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-11-23 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2020-09-29 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-05-11 |
| — | Stifel | Buy | — | — | Reiterated | 2020-03-17 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2019-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2019-11-05 |
| — | Janney Capital | Buy | — | — | Reiterated | 2019-09-09 |
| — | Bank of America | Underperform | — | — | Downgraded | 2018-10-16 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2018-10-16 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2018-05-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2018-02-09 |
| — | Bank of America | Neutral | — | — | Reiterated | 2017-11-27 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2017-11-27 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2017-11-27 |
SPRO earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-26 | -0.20 | 0.53 | $26.0M | $41.3M |
| 2026-05-13 | -0.18 | -0.13 | $258K | $258K |
| 2026-08-12 | -0.17 | -0.16 | $0 | $0 |
| 2026-11-12 | -0.14 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.